Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nektar Therapeutics ( (NKTR) ) has shared an announcement.
On February 10, 2025, Nektar Therapeutics reported positive 36-week blinded maintenance results from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis. Monthly and quarterly dosing of the Treg biologic maintained robust EASI-75, EASI-90, vIGA-AD 0/1 and itch responses at week 52, highlighted by 71% and 83% EASI-75 maintenance rates for 24 µg/kg monthly and quarterly dosing, respectively.
The study also showed meaningful deepening of response over time, including two- to five-fold increases in complete clearance (EASI-100) rates, with conversions up to 30% among certain responder subsets by week 52. Rezpegaldesleukin’s safety profile remained favorable and consistent with induction, with low discontinuations and mostly mild injection-site reactions, supporting its potential as a differentiated, less frequently dosed therapy and underpinning Nektar’s move toward Phase 3 development in atopic dermatitis.
The most recent analyst rating on (NKTR) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and high leverage. Despite technical indicators suggesting bearish momentum, the company’s strong cash position and promising clinical trial results for REZPEG provide some optimism. The recent corporate events and positive earnings call sentiment contribute positively, but the financial challenges remain a significant concern.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics, based in San Francisco and listed on Nasdaq as NKTR, is a clinical-stage biotechnology company developing novel immunology therapies. Its lead candidate in atopic dermatitis, rezpegaldesleukin, is a first-in-class regulatory T-cell biologic designed as an immune modulator for patients with moderate-to-severe disease, positioning the firm in the competitive inflammatory skin disorder market.
On February 10, 2025, Nektar reported positive 36-week blinded maintenance data from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis. Monthly and quarterly dosing maintained high EASI-75 and vIGA-AD 0/1 response rates and produced up to a five-fold rise in complete skin clearance (EASI-100), with a favorable, consistent safety profile and mild injection-site reactions, reinforcing the drug’s potential best-in-class profile and supporting advancement to pivotal Phase 3 studies.
Average Trading Volume: 773,547
Technical Sentiment Signal: Hold
Current Market Cap: $748.8M
Find detailed analytics on NKTR stock on TipRanks’ Stock Analysis page.